



Tanya Dorff

Kontakt

Tanya Dorff

Publikationen (2)

Kelly W, Danila D, Lin C, Lee J, Matsubara N, Ward P, Armstrong A, Pook D, Kim M, Dorff T, Fischer S, Lin Y, Horvath L, Sumey C, Yang Z, Jurida G, Smith K, Connarn J, Penny H, Stieglmaier J, Appleman L. Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study. *Cancer Discov* 2023;OF1-OF14.

Gordon J, Cox M, De Placido P, Ribera D, Omlin A, Buonocore G, Chi K, Kollmannsberger C, Khalaf D, Facchini G, Sonpavde G, De Placido S, Eogl B, Cherhroudi C, Pignata S, Battaglia M, Buonerba C, Pond G, Crona D, Gillessen Sommer S, Lucarelli G, Rossetti S, Dorff T, Artale S, Locke J, Bosso D, Milowsky M, Witek M, Di Lorenzo G. Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study. *Oncotarget* 2018; 9:19861-19873.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch